Send to

Choose Destination
Pulm Circ. 2014 Jun;4(2):342-5. doi: 10.1086/675996.

Imatinib for the treatment of pulmonary arterial hypertension and pulmonary capillary hemangiomatosis.

Author information

St. Vincent's Hospital, Sydney, Australia ; University of New South Wales, Kensington, Australia.
St. Vincent's Hospital, Sydney, Australia.


Despite currently available treatments, the prognoses of pulmonary arterial hypertension (PAH) and pulmonary capillary hemangiomatosis (PCH) remain poor. Platelet-derived growth factor and its receptor (PDGFR) have been implicated in the pathogenesis of pulmonary hypertension in PAH and PCH. Imatinib, a PDGFR antagonist, may be beneficial in the treatment of both conditions because of its potent antiproliferative effect. We report two cases that demonstrate the potential for safe and efficacious use of imatinib in PAH and PCH.

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center